ProgressImage ProgressImage
Gland Pharma Ltd
Pharmaceuticals - Indian - Formulations
BSE Code 543245 border-img ISIN Demat INE068V01023 border-img Book Value 655.29 border-img NSE Symbol GLAND border-img Div & Yield % 0.68 border-img Market Cap ( Cr.) 48374.82 border-img P/E 34.25 border-img EPS 85.62 border-img Face Value 1
ParticularsMar 2026
()
Mar 2025
()
Mar 2024
()
Mar 2023
()
Mar 2022
()
Mar 2021
()
INCOME :       
Sales Turnover 4552.094116.154167.433616.534400.713462.88
Excise Duty 0.000.000.000.000.000.00
Net Sales 4552.094116.154167.433616.534400.713462.88
Other Income 303.90215.08166.67240.46223.94134.78
Stock Adjustments 6.67-130.25-87.4346.92-36.69273.49
Total Income 4862.664200.984246.673903.914587.963871.15
EXPENDITURE :       
Raw Materials 1801.821600.351732.881732.342072.531765.36
Power & Fuel Cost 122.38120.38117.20124.8495.0574.59
Employee Cost 528.82439.02409.95399.70338.57311.36
Other Manufacturing Expenses 209.14188.89186.92153.84137.19130.84
Selling & Administrative Expenses 197.33155.54175.97189.65177.43128.44
Miscellaneous Expenses 60.5339.1048.31100.9932.6123.51
Less : Pre-operative Expenses Capitalised 0.000.000.000.000.000.00
Total Expenditure 2920.022543.292671.222701.352853.382434.10
Operating Profit 1942.621657.701575.441202.551734.581437.04
Interest 18.0722.847.847.415.243.41
Gross Profit 1924.551634.861567.601195.141729.341433.63
Depreciation 176.24169.27162.11146.74110.3098.78
Profit Before Tax 1748.311465.591405.491048.401619.041334.85
Tax 452.59366.71337.49275.38392.88337.73
Fringe Benefit tax 0.000.000.000.000.000.00
Deferred Tax -3.839.1224.68-2.8014.010.12
Reported Net Profit 1299.551089.751043.33775.831212.16997.01
Extraordinary Items -15.681.64-0.39-39.553.220.02
Adjusted Net Profit 1315.231088.111043.72815.381208.94996.99
Adjustment below Net Profit 0.000.000.000.000.000.00
P & L Balance brought forward 7814.287054.036010.705234.884022.723025.72
Statutory Appropriations 0.000.000.000.000.000.00
Appropriations 296.56329.500.000.000.000.00
P & L Balance carried down 8817.277814.287054.036010.705234.884022.72
Dividend 0.000.000.000.000.000.00
Preference Dividend 0.000.000.000.000.000.00
Equity Dividend % 2000.001800.002000.000.000.000.00
Dividend Per Share(Rs) 20.0018.0020.000.000.000.00
Earnings Per Share-Unit Curr 78.8866.1463.3447.1173.7860.95
Earnings Per Share(Adj)-Unit Curr 78.8866.1463.3447.1173.7860.95
Book Value-Unit Curr 656.11592.08546.13482.90435.68360.86
Book Value(Adj)-Unit Curr 656.11592.08546.13482.90435.68360.86
`

ATTENTION INVESTORS : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day ...Issued in the interest of investors.   Prevent Unauthorized Transactions in your demat account Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day...... issued in the interest of investors.    KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.      No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment.No worries for refund as the money remains in investor's account.

Investor Protection and Arbitration Exchange Circulars and Rules - NSE BSE

Filing of complaints on SCORES – Easy & quick   |    Advisory for Investors   |    AP Details - NSE   |    AP Details - BSE   |    AP Details - MCX
KYC Process Flow   |    Investor Grievance Redressal Process Flow   |   Online Grievance Redressal   |    Voluntary Freezing/Blocking of Trading Account   |    Website Accessibility Statement   |    CDSL MyEasi   |    TRAI Notice on UCC   |    SEBI Risk Disclosure   |    Investor Notice

Disclaimer : Investment in securities market are subject to market risks, read all the related documents carefully before investing. Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

x
x
×
Let's Chat
imsl-img
close
refresh